We report the case of a child from Central Brazil with global developmental delay (GDD), syndromic features, and absence of abnormal skin pigmentation, nail dystrophy, and leukoplakia of the oral mucosa, with a rearrangement at Xq28 harboring the DKC1 gene. GTC-banding revealed a male karyotype (46,XY) with no visible numerical or structural alterations. Chromosomal microarray analysis (CMA) showed a 0.36-Mb gain at Xq28 of maternal origin, encompassing 22 genes, including DKC1. Rearrangements and mutations involving this gene have been associated with dyskeratosis congenita, X-linked (OMIM 305000) and Hoyeraal-Hreidarsson syndrome. CMA was a powerful and efficient approach to identify a gain at Xq28 harboring the DKC1 gene in our patient with GDD syndromic features and no cutaneous alterations, suggesting that this variant is associated with the Hoyeraal-Hreidarsson syndrome.

Keywords:
Chromosomal microarray analysis, DKC1, Genetic syndrome, Global developmental delay
1.
Aalfs CM, van den Berg H, Barth PG, Hennekam RC: The Hoyeraal-Hreidarsson syndrome: the fourth case of a separate entity with prenatal growth retardation, progressive pancytopenia and cerebellar hypoplasia. Eur J Pediatr 154:304-308 (1995).
2.
Alder JK, Parry EM, Yegnasubramanian S, Wagner CL, Lieblich LM, et al: Telomere phenotypes in females with heterozygous mutations in the dyskeratosis congenita 1 (DKC1) gene. Hum Mutat 34:1481-1485 (2013).
3.
Bakar Ö, Işik U, Canpolat C, Alanay Y: Hoyeraal-Hreidarsson syndrome: an extremely rare dyskeratosis congenita phenotype. Pediatr Dermatol 32:263-266 (2015).
4.
Capalbo A, Rienzi L, Ubaldi FM: Diagnosis and clinical management of duplications and deletions. Fertil Steril 107:12-18 (2017).
5.
Dehmel M, Brenner S, Suttorp M, Hahn G, Schützle H, et al: Novel mutation in the DKC1 gene: neonatal Hoyeraal-Hreidarsson syndrome as a rare differential diagnosis in pontocerebellar hypoplasia, primary microcephaly, and progressive bone marrow failure. Neuropediatrics 47:182-186 (2016).
6.
Glousker G, Touzot F, Revy P, Tzfati Y, Savage SA: Unraveling the pathogenesis of Hoyeraal-Hreidarsson syndrome, a complex telomere biology disorder. Br J Haematol 170:457-471 (2015).
7.
Gu BW, Bessler M, Mason PJ: A pathogenic dyskerin mutation impairs proliferation and activates a DNA damage response independent of telomere length in mice. Proc Natl Acad Sci USA 105:10173-10178 (2008).
8.
Hiroi N, Takahashi T, Hishimoto A, Izumi T, Boku S, Hiramoto T: Copy number variation at 22q11.2: from rare variants to common mechanisms of developmental neuropsychiatric disorders. Mol Psychiatry 18:1153-1165 (2013).
9.
Hoyeraal HM, Lamvik J, Moe PJ: Congenital hypoplastic thrombocytopenia and cerebral malformations in two brothers. Acta Pediatr Scand 59:185-191 (1970).
10.
Hreidarsson S, Kristjansson K, Johannesson G, Johannsson JH: A syndrome of progressive pancytopenia with microcephaly, cerebellar hypoplasia and growth failure. Acta Pediatr Scand 77:773-775 (1988).
11.
Mochizuki Y, He J, Kulkarni S, Bessler M, Mason PJ: Mouse dyskerin mutations affect accumulation of telomerase RNA and small nucleolar RNA, telomerase activity, and ribosomal RNA processing. Proc Natl Acad Sci USA 101:10756-10761 (2004).
12.
Muthusamy B, Selvan LDN, Nguyen TT, Manoj J, Stawiski EW, et al: Next-generation sequencing reveals novel mutations in X-linked intellectual disability. OMICS 21:295-303 (2017).
13.
Rafati M, Seyyedaboutorabi E, Ghadirzadeh MR, Heshmati Y, Adibi H, et al: “Familial” versus “Sporadic” intellectual disability: contribution of common microdeletion and microduplication syndromes. Mol Cytogenet 5:9 (2012).
14.
Verma RS, Babu A: Human Chromosomes: Principles and Techniques (McGraw-Hill Inc., New York 1995).
15.
Xu J, Khincha PP, Giri N, Alter BP, Savage SA, Wong JM: Investigation of chromosome X inactivation and clinical phenotypes in female carriers of DKC1 mutations. Am J Hematol 91:1215-1220 (2016).
© 2019 S. Karger AG, Basel
2019
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.